Category: 3. Business

  • US dollar drops and stock markets face losses after Trump announces 15% global tariff – business live | Business

    US dollar drops and stock markets face losses after Trump announces 15% global tariff – business live | Business

    Introduction: Dollar and stocks decline after US Supreme Court hits Trump’s tariffs

    Good morning, and welcome to our rolling coverage of business, the financial markets and the world economy.

    We’re in a new phase of trade war uncertainty, after the supreme court blocked Donald Trump’s sweeping global tariffs last Friday.

    With the president hitting back over the weekend, announcing a new temporary global tariff of 10%, then 15%, its clear that the White House is persisting with its policy of using trade levies to gain leverage over other countries.

    So, as ING economists warn:

    double quotation markAnnouncements since the Supreme Court’s ruling strongly confirm that Trump has no intention of removing his “most beautiful word” from the English dictionary.

    Uncertainty is back, and given the latest muscle-flexing by European leaders, the risk of escalation is now higher than it was a year ago.

    The market reaction has been to sell the US dollar – it has fallen by 0.4% against a basket of other currencies today, adding to losses on Friday after the supreme court declared tariffs imposed under the International Emergency Economic Powers Act to be illegal.

    US stock market futures are lower too, indicating we’ll see losses on Wall Street, while bitcoin has also weakened.

    Last night, US Trade Representative Jamieson Greer insisted that deals made with other countries are still intact, and should be honoured.

    Greer told CBS’s Face the Nation:

    double quotation mark“We want them to understand these deals are going to be good deals.

    “We’re going to stand by them. We expect our partners to stand by them.”

    Greer also pledged that the new 15% global tariff was distinct from the bilateral agreements struck in the last nine months with about 20 countries.

    That indicates that the deal announced by Trump and the UK prime minister, Keir Starmer, in May last year will continue to stand, rather than the UK’s tariff rising to 15%.

    Although, as education secretary, Bridget Phillipson admitted on Sunday, UK businesses faced “uncertainty” after the latest developments.

    The agenda

    • 9am GMT: German IFO investor confidence survey

    • Noon GMT: Mexico’s Q4 2025 GDP report

    • 1.30pm GMT: The Chicago Fed National Activity Index

    • 3pm GMT: US factory orders for December

    Share

    Key events

    Australia’s stock market drops but Hong Kong rallies

    Asia-Pacific stock markets have already reacted to the latest tariff developments.

    Australia’s stock market has dropped by 0.6%, as investors recognise that the new 15% global tariff will hurt its exporters.

    But with mainland Chinese markets closed for the lunar new year, Hong Kong’s Hang Seng index has surged by 2.4%.

    That follows analysis (see here) showing that China is one of the countries who should benefit most from the new global tariff.

    Tony Sycamore, market analyst at IG, explains:

    double quotation markEven after President Trump’s swift response—announcing a new 10% global tariff (quickly raised to 15%) under Section 122 of the Trade Act of 1974, effective February 24, the net tariff on Chinese goods is still lower than it was before the Court ruling. Most estimates suggest that China will see a net reduction in tariffs of roughly 5–8 percentage points versus the pre-ruling IEEPA peak.

    While it’s good news for China, the news isn’t so good for Australia, as Australia’s effective US tariff rate on many of its exports is rising from a 10% baseline to 15%—a 50% relative increase under the new temporary global surcharge announced by President Trump.

    Share

    Continue Reading

  • REVIEWED FINANCIAL RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2025 AND UPDATED BUSINESS OUTLOOK

    JOHANNESBURG, Feb. 23, 2026 /PRNewswire/ — Sasol has released its operating and financial results for the six months ended 31 December 2025 (H1 FY26).

    Highlights:

    • Turnover of R122,4 billion remained flat compared to prior period, supported by 3% increase in sales volumes and despite the softer macro environment
    • Secunda Operations’ (SO) production volumes 10% higher
    • Lower cash fixed cost compared to the prior period, reflecting disciplined cost management
    • Adjusted EBITDA of R21,0 billion, 12% lower than the prior period
    • Earnings before interest and tax (EBIT) of R4,6 billion, 52% lower than the prior period
    • Headline earnings per share (HEPS) of R9,27 per share, 34% lower than the prior period
    • Capital expenditure of R8,5 billion, 43% lower than the prior period
    • Free cash flow improvement to R0,8 billion, more than 100% change from the prior period
    • Net debt (excluding leases) of R63,3 billion (US$3,8 billion), representing a net debt to Adjusted EBITDA ratio of 1,6 times
    • FY26 hedging programme concluded, with FY27 hedging programme underway

    Statement by Simon Baloyi, Chief Executive Officer of Sasol:
    We are showing consistent progress in the implementation of our strategic initiatives as set out in our Capital Markets Day plan. This is strengthening our foundation business, helping us to mitigate ongoing global market volatility and macroeconomic headwinds, building resilience for the future.

    Safety remains our foremost value, and we endeavour to send everyone home safely each day. Unfortunately, we did not, as we lost one of our team members in September 2025. While this loss weighs heavily on us, we are seeing an encouraging improvement in key leading safety indicators. Our commitment to safety remains unwavering as we continue to embed learnings and reinforce a strong safety culture across the business.

    In the Southern Africa business, we achieved an important milestone in December 2025 when the destoning plant at Sasol Mining reached beneficial operation in line with plan and improving coal quality. This, together with higher gasifier availability and no phase shutdown, resulted in a 10% uplift in Secunda Operations’ (SO) production volumes. Disciplined cost and capital management further supported a lower cash break-even oil price.

    The International Chemicals reset strategy is progressing, although market conditions were weaker than anticipated with lower US ethylene margins and muted market demand. We have made good progress on lowering our cost base, which supported a 10% increase in Adjusted EBITDA in US$ terms compared to the prior period.

    The Group generated positive free cash flow in the first half of the financial year for the first time in four years, despite the challenging macro environment. This was supported by the higher sales volumes, lower cash fixed costs and lower capital expenditure. Importantly, this has been achieved without compromising asset integrity and safety.

    The balance sheet remains a focus area with robust liquidity in place while we continue to hedge proactively to manage downside risk.

    We continue to advance our Grow and Transform strategy. We have secured an additional 300 megawatt (MW) of renewable energy, increasing total secured capacity in South Africa to more than 1 200 MW, supporting both emission reductions and cost savings.

    Our priorities are clear: safe, reliable operations; disciplined cost and capital management; proactive risk management; and improved cash generation. Consistent execution in these areas is strengthening resilience and positioning Sasol to deliver sustainable shareholder value.”

    Financial performance

    Sasol continued to make progress on factors within its control despite a challenging macro environment. Lower cost and capital expenditure supported positive free cash flow generation in the period.

    Adjusted EBITDA of R21,0 billion was 12% lower than the prior period, primarily due to a 17% decline in the average Rand per barrel Brent crude oil price and lower average US dollar per ton chemicals basket price. This was partially offset by improved refining margins, 3% higher sales volumes driven by stronger production performance and lower cash fixed costs.

    Earnings before interest and tax (EBIT) of R4,6 billion was 52% lower than the prior period of R9,5 billion and impacted by non-cash remeasurement items of R7,9 billion. This related mainly to impairments of R7,8 billion (before tax) compared to R5,7 billion in the prior period, and include the impairment on the Secunda liquid fuels refinery cash generating unit (CGU) and our Mozambican Production Sharing Agreement (PSA) gas development.

    As a result of the above, basic earnings per share (EPS) decreased by 95% to R0,38 per share and HEPS decreased by 34% to R9,27 per share compared to the prior period.

    Cash generated by operating activities of R11,6 billion declined 34%, mainly reflecting the lower earnings detailed above. Capital expenditure of R8,5 billion was 43% lower than the prior period. This was mainly due to no Secunda shutdown, lower Production Sharing Agreement (PSA) project expenditure in Mozambique and lower capital on environmental compliance programmes as these near completion. Free cash flow of R0,8 billion increased by more than 100%, supported by the lower capital expenditure.

    Liquidity remains robust at above US$4 billion and we actively manage our debt maturity profile, maintaining resilience in a volatile market environment.

    Total debt decreased to R93,5 billion (US$5,6 billion) compared to R103,3 billion (US$5,8 billion) at 30 June 2025. Sasol deposited R8,7 billion (US$500 million) on the revolving credit facility and repaid R812 million on the DMTN. A floating rate bond of R5,3 billion was issued in the period to 31 December 2025. In exchange, US$300 million was received. The issuance supports our efforts to diversify the funding base, reduce US$ dollar debt exposure and financing costs. In addition, it provides the flexibility to address upcoming bond maturities using available liquidity if required.

    Net debt (excluding leases) ended at R63,3 billion (US$3,8 billion), compared to R65,0 billion (US$3,7 billion) at 30 June 2025. We continue to prioritise cash generation through our management actions to meet our full-year net debt target of below US$3,7 billion.

    We continue to execute our hedging strategy, with the FY26 programme complete and the FY27 hedging programme underway. During the period, foreign exchange translation losses were largely offset by gains on derivative instruments. Given the prevailing market conditions, a broader range of hedging instruments has been utilised to maintain downside protection.

    Key metrics


    Half year
    31 Dec 2025

    Half year
    31 Dec 2024

    Change %

    Turnover (R million)

    122 387

    122 102

    Adjusted EBITDA1 (R million)

    21 006

    23 949

    (12)

    EBIT (R million)

    4 619

    9 533

    (52)

    Basic earnings per share (Rand)

    0,38

    7,22

    (95)

    Headline earnings per share (Rand)

    9,27

    14,13

    (34)

    Capital expenditure (R million)

    8 495

    15 007

    (43)

    Free cash flow2 (R million)

    794

    (1 296)

    >100

    Net debt (excluding leases)3 (R million)

    63 269

    64 964

    3

    1  Adjusted EBITDA is calculated by adjusting operating profit for depreciation, amortisation, share-based payments, remeasurement items, change in discount rates of our rehabilitation provisions, all unrealised translation gains and losses, and all unrealised gains and losses on our derivatives and hedging activities.

    2  Free cash flow is defined as cash available from operating activities less first order capital and related capital accruals.

    3  Comparative number is as at 30 June 2025.

    Net asset value

    Half year
    31 Dec 2025

    Full year
    30 Jun 2025

    Change %

    Total assets (R million)

    339 707

    359 555

    (6)

    Total liabilities (R million)

    183 010

    201 944

    9

    Total equity (R million)

    156 697

    157 611

    (1)

    Turnover


    EBIT/(LBIT)1

    Half year
    31 Dec 2025

    Half year
    31 Dec 2024


    Half year
    31 Dec 2025

    Half year
    31 Dec 2024

    R million

    R million


    R million

    R million



    Southern Africa Energy and
    Chemicals



    14 744

    15 347

    Mining

    2 138

    2 291

    6 342

    6 591

    Gas

    (811)

    3 925

    52 046

    48 845

    Fuels

    3 082

    (998)

    28 917

    30 748

    Chemicals Africa

    (293)

    3 469



    International Chemicals



    19 010

    19 724

    America

    550

    657

    20 932

    19 921

    Eurasia

    255

    (136)

    Business Support

    (302)

    325

    141 991

    141 176

    Group performance

    4 619

    9 533

    (19 604)

    (19 074)

    Intersegmental turnover


    122 387

    122 102

    External turnover


    1  Loss before interest and tax


    Dividend

    The Company’s dividend policy is based on 30% of free cash flow generated, provided that net debt (excluding leases) is sustainably below US$3 billion. The net debt at 31 December 2025 of US$3,8 billion exceeds the net debt trigger, therefore no interim dividend was declared by the Sasol Limited board of directors (the Board).

    Updated business outlook

    The Group remains on track to achieve its previously communicated guidance, with the following revisions:

    • Capital expenditure expected to be between R22 – R24 billion, R2 billion lower than the previous guidance of R24 – R26 billion due to ongoing capital optimisation initiatives; and
    • International Chemicals Adjusted EBITDA is revised lower to US$375 to US$450 million, (previously US$450 to – US$550 million) and Adjusted EBITDA margin 8% to 10% (previously 10% to 13%). This is due to a combination of weaker macroeconomic assumptions, softer market conditions and the unplanned Louisiana Integrated Polyethylene JV LLC ethylene cracker outage in Q2FY26. Self-help measures continue to be progressed.

    The operating environment is expected to remain challenging, given heightened geopolitical tensions, evolving global trade dynamics and continued softness in certain end markets impacting financial performance. Our focus on safe and reliable operations and realising more value from our self-help initiatives will enable stronger free cash flow generation, deleveraging and sustainable value for our stakeholders.

    The information contained in this paragraph has not been reviewed or reported on by Sasol’s auditors. More details on our financial year 2026 outlook is available in our Interim results presentation available on the Company´s website at www.sasol.com, under the Investor Centre section: https://www.sasol.com/investor-centre/financial-results

    Short-form statement

    This announcement has been prepared in compliance with the JSE Listings Requirements and is the responsibility of the Board and is only a summary of the information in Sasol Limited’s condensed consolidated interim financial statements for the six months ended 31 December 2025. The condensed consolidated interim financial statements have been reviewed by Sasol’s external auditors, KPMG, who expressed an unmodified review conclusion thereon. Financial figures in this announcement have been correctly extracted from the condensed consolidated interim financial statements. The information in this announcement has not been reviewed and reported on by Sasol Limited’s external auditors.

    Any investment decision should also take into consideration the information contained in the full condensed consolidated interim financial statements, published on SENS on 23 February 2026, via the JSE link. The condensed consolidated interim financial statements, including KPMG’s unmodified review conclusion, are available through a secure electronic manner at the election of the person requesting inspection, and have been published and can be found on the company’s website, https://www.sasol.com/index.php/investor-centre/financial-results, and can also be viewed on the JSE link, https://senspdf.jse.co.za/documents/2026/JSE/ISSE/SOL/HY26Result.pdf 

    Important information

    Sasol will present its interim financial results for the six months ended 31 December 2025 on Monday, 23 February 2026 at 11h00 (SA time). This will be followed by a market call, hosted by the President and Chief Executive Officer, Simon Baloyi, and Chief Financial Officer, Walt Bruns, to address questions.

    Please connect to the call via the webcast link: https://www.corpcam.com/Sasol23022026
    or via teleconference call link: https://services.choruscall.eu/DiamondPassRegistration/register?confirmationNumber=3605690&linkSecurityString=89ae33f44

    A recording of the presentation will be available on the website thereafter at https://www.sasol.com/investor-centre/financial-results.

    For further information, please contact:
    Sasol Investor Relations
    Tiffany Sydow, VP Investor Relations
    Telephone: +27 (0) 71 673 1929
    Email: [email protected]
    Website : https://www.sasol.com/investor-centre/financial-results.

    Disclaimer – Forward-looking statements

    Sasol may, in this document, make certain statements that are not historical facts, based on management’s current views and assumptions, and which are conditioned upon and also involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those anticipated by such statements. Should one or more of these risks materialise, or should underlying assumptions prove incorrect, our actual results may differ materially from those anticipated.  Examples of such forward-looking statements include, but are not limited to, the capital cost of our projects and the timing of project milestones; our ability to obtain financing to meet the funding requirements of our capital investment programme, as well as to fund our ongoing business activities and to pay dividends; statements regarding our future results of operations and financial condition, and regarding future economic performance including cost containment, cash conservation programmes and business optimisation initiatives;  our business strategy, performance outlook, plans, objectives or goals; statements regarding future competition, volume growth and changes in market share in the industries and markets for our products; our existing or anticipated investments, acquisitions of new businesses or the disposal of existing businesses, including estimates or projection of internal rates of return and future profitability; our estimated oil, gas and coal reserves; the probable future outcome of litigation, legislative, regulatory and fiscal developments, including statements regarding our ability to comply with future laws and regulations; future fluctuations in refining margins and crude oil, natural gas and petroleum and chemical product prices; the demand, pricing and cyclicality of oil, gas and petrochemical products; changes in the fuel and gas pricing mechanisms in South Africa and their effects on costs and product prices, statements regarding future fluctuations in exchange and interest rates and changes in credit ratings; assumptions relating to macroeconomics, including changes in trade policies, tariffs and sanction regimes; the impact of climate change, our development of sustainability within our businesses, our energy efficiency improvement, carbon and greenhouse gas emission reduction targets, our net zero carbon emissions ambition and future low-carbon initiatives, including relating to green hydrogen and sustainable aviation fuel;  our estimated carbon tax liability; cyber security; and statements of assumptions underlying such statements.

    Words such as “believe”, “anticipate”, “expect”, “intend”, “seek”, “will”, “plan”, “could”, “may”, “endeavour”, “target”, “forecast” and “project” and similar expressions are intended to identify forward-looking statements but are not the exclusive means of identifying such statements. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and there are risks that the predictions, forecasts, projections, and other forward-looking statements will not be achieved.  These risks and uncertainties are discussed more fully in our most recent annual report on Form 20-F filed on 29 August 2025 and in other filings with the United States Securities and Exchange Commission. The list of factors discussed therein is not exhaustive; when relying on forward-looking statements to make investment decisions, you should carefully consider both the foregoing factors and other uncertainties and events, and you should not place undue reliance on forward-looking statements. Forward-looking statements apply only as of the date on which they are made, and we do not undertake any obligation to update or revise any of them, whether as a result of new information, future events or otherwise.

    Please note: One billion is defined as one thousand million, bbl – barrel, bscf – billion standard cubic feet, mmscf – million standard cubic feet, oil references Brent crude, mmboe – million barrels oil equivalent. All references to years refer to the financial year ending 30 June. Any reference to a calendar year is prefaced by the word “calendar”.

    SOURCE Sasol Limited

    Continue Reading

  • Private equity resurgence gathers steam as new era challenges firms to enhance value creation–Bain & Company Global PE Report

    Private equity resurgence gathers steam as new era challenges firms to enhance value creation–Bain & Company Global PE Report

    • Rebound in dealmaking lifts buyouts and exits to second highest values on record, with a sustained upswing in prospect
    • Industry reaches critical inflection point as intensified competition challenges funds to deliver differentiated strategies and high performance
    • ’12 is the new 5′ – Bain coins a rule of thumb capturing new math for a new era in PE

    BOSTON and LONDON, Feb. 23, 2026 /PRNewswire/ — A resurgence in global private equity is gathering steam after a rebound in dealmaking last year that saw both buyout deals and exits surge ahead to register their second highest values on record. After three prior years in the relative doldrums, the advances mark a turning point for PE and set the stage for a continuing revival in 2026 and beyond, Bain & Company’s 17th annual Global PE Report, released today, concludes.

    But Bain’s analysis tempers this upbeat message on brightening prospects, with a caution that the maturing PE industry has reached a critical inflection point. PE firms confront greatly heightened competition for capital as well as intensified investor demands for high performance – even as they continue to contend with a series of stubborn industry challenges, today’s report warns.

    Even with last year’s leap in exit value, amounts of cash flowing back to limited partner (LP) investors continue to disappoint, hampering PE’s revitalization, Bain finds. The key measure of this, distributions to LPs as a percentage of net asset value (NAV), has now been mired below 15% for four consecutive years, setting an industry record. The industry’s liquidity logjam comes as it sits on a stock of 32,000 unsold companies worth a stunning $3.8 trillion, Bain notes. For buyout funds, holding periods at exit now hover at around seven years – up from an average of five to six years from 2010 to 2021. In turn, lagging distributions to LPs are the main driver of a slow and difficult slog faced by many PE firms in fund-raising, the analysis concludes.

    Despite the challenges of these structural issues, as well as lingering economic uncertainties, today’s report charts how last year saw PE get moving once again as an industry recovery gained traction amid some of the biggest buyouts of all time.

    Pent-up appetite among general partners (GPs) to get deals done and put to work a $1.3 trillion arsenal of global buyout dry power – much of it aging, along with falling interest rates, catalyzed a sharp rebound in deal and exit values, with confidence returning to credit markets. 2025 global buyout deal value (excluding add-ons) leapt 44% year-on-year to $904 billion. The $56.6 billion public-to-private deal for Electronic Arts (EA) set a new all-time buyout record.

    Alongside, exits also rebounded, with global buyout-backed exit value jumping 47% year-on-year to $717 billion, led by a series of landmark exits, including Macquarie’s $40 billion sale of Aligned Data Centers to BlackRock and a consortium of tech giants hungry for AI data-crunching capacity.

    However, while both buyout and exit values were the second highest ever, and not far behind those in PE’s zenith year in 2021 – and while the year also saw some of PE’s biggest-ever transactions – Bain’s report cautions that the 2025 recovery was also markedly narrow. Just 13 megadeals in the $10 billion-plus bracket accounted for $274 billion (or 30%) of the global total, with 11 of those deals being concentrated in the US.

    “The good news is 2026 is shaping up as promising. Interest rates are moving south, if slowly, deal pipelines are well stocked. With stock prices high and the economy robust – and barring another ‘black swan’ jolt to the system – the conditions for deal and exit activity are rosier than for some time,” Hugh MacArthur, chairman of the global Private Equity practice at Bain & Company, said. “Beneath the headline recovery, though, there is a more uneven underlying reality – and plenty of work still to do. Deal value has been highly concentrated in megadeals, favoring a few scale players. Many GPs continue to face pressures from longer holding periods, constrained distributions, and fund-raising conditions that are among the toughest the industry has experienced. With the tailwinds that propelled the industry forward in the 2010s gone, the dynamics mean that most players will have to substantially raise their value creation game.”

    The changed dynamics challenging GPs that have made the PE business model significantly more complex to execute on than in the industry’s ‘golden decade’ of the 2010s are examined in detail in Bain’s report. While that period provided PE players with powerful tailwinds from rock-bottom interest rates, steadily rising valuation multiples, and ready access to investors and capital, Bain finds that today’s new baseline is higher rates, stubbornly high valuations, slower exits and much choosier investors. At the same time, PE firms’ costs are rising as leading firms build competitive moats through scale, expertise, technology and AI, and professionalized fund-raising.

    Rebecca Burack, head of the global Private Equity practice at Bain & Company, said: “Against this backdrop, deal math is only getting harder. The industry is at an inflection point having reached a level of maturity that comes to all sectors, where competition intensifies and customers, in this case investors, demand a much higher degree of excellence. More than ever, investors are focused on funds that have a clear, repeatable, easily explained strategy for delivering top-tier results. In the new era we are entering, the performance that winning firms need to deliver will rely on their ability to rapidly generate strong EBITDA growth, full stop.”

    New math for a new era: Bain sets out a rule of thumb capturing why ’12 is the new 5′ for PE

    As a new cycle for PE gathers steam, with an upswing in dealmaking in a context where every aspect of raising capital and generating returns is more challenging, Bain sets out a rule of thumb to capture the implications for the industry that it calls “12 is the new 5”.

    During PE’s ‘golden decade’ of the 2010s, based on typical deal pricing, capital structure and exit values, and with dealmakers benefiting from then substantial valuation multiple expansion, a typical PE investment required only 5% annual growth in earnings before interest, taxes, depreciation and amortization (EBITDA) to generate a target 2.5X multiple on invested capital (MOIC) over average five-year holding periods. This level of earnings would also deliver a 20 per cent internal rate of return (IRR).

    Yet in today’s environment, with borrowing costs in the 8% to 9% range, leverage ratios of 30% to 40%, and purchase multiples in record territory, the lower leverage and lack of multiple expansion make value creation more challenging. In turn, Bain finds that typical deals now require around a 10% to 12% average annual growth in EBITDA to generate the same benchmark 2.5X return over five years.

    The consequences of “12 is the new 5” mean that most PE funds will need to substantially raise their value creation game in these changed circumstances – with pressure intensified as LPs increasingly narrow their focus to the largest platforms and firms that are top-tier generators of alpha, Bain concludes. At the same time, firms’ costs to generate performance are being driven up by the need for heavy investments in specialized sector expertise, critical capabilities, technology and talent, while revenues to pay for these requirements are under pressure from falling management fees as well as LPs’ growing appetite for co-investment.

    Rebecca Burack commented: “Generating attractive returns now requires significantly more operational improvement and revenue growth. We call this ’12 is the new 5′.  In practical terms, deals that once delivered competitive returns with modest EBITDA growth now require sustained, double-digit growth. In PE’s new upcycle, the winners will be those for whom alpha generation is a habit, not an aspiration. The winning firms will be those that build true differentiation, whether through scale, specialization or superior execution, and turn that differentiation into a system, not a slogan, and one that is backed up by data.” 

    Bain’s report advocates that, increasingly, successful PE players will secure competitive advantage in the era where ’12 is the new 5′ by proactively identifying potential deal targets as far as years ahead of any deal. It also urges that, in the new era, firms that want to ensure robust value creation will need to focus on not only a viable deal case but on the true full potential of an asset through what Bain calls “full potential due diligence” that scrutinizes revenue, operational and technology levers that can deliver a step-change in a portfolio company’s performance.

    A year of two halves puts PE in a new upswing, driven by a wave of megadeals

    Charting PE’s 2025 upswing, today’s report notes that having begun last year with optimism, investors quickly regained their footing after the setback of turmoil around the US administration’s tariff announcements in April, with dealmaking then staging a potent rebound from Q3, which registered PE’s strongest quarter ever, with an impressive $301 billion in deal value.

    But while deal value for the year was close to record highs – flattered by an average disclosed deal size that marked an all-time record of $1.2 billion – the number of buyout deals declined, falling by 6% year-on-year, to register 3,018 transactions.  A wave of megadeals wowed the market and drove the steep jump in total deal value. In addition to the record $56.6 billion public-to-private deal for EA and the $40 billion deal for Aligned Data Centers were the $27.5 billion acquisition of Air Lease, the air leasing platform, and the $23.7 billion deal for Walgreens Boots Alliance, the retail pharmacy chain.

    Yet Bain also notes that these huge numbers also belied relatively modest impact on the buyout industry’s $1.3 trillion mountain of dry powder, with the bulk of equity in many transactions coming from external sources, especially sovereign wealth funds and corporate buyers, rather than PE funds. After taking into account the extensive availability of such non-buyout capital, the amount of money chasing deals is unprecedented – and cutting into PE’s share of the action, the report finds.

    Activity below the megadeal threshold was meanwhile more representative of the state of the buyout market amid macro uncertainties, Bain suggests. Excluding the $10 billion-plus deal segment, 2025 deal value grew 16% year-on-year, with transactions in the $5 billion to $10 billion range growing 6%, while the $1 billion to $5 billion segment grew 29%.

    North America was by far the biggest driver of dealmaking, adding 80% to the deal value – although Europe made a comparable contribution if the megadeals above $10 billion are removed from the total. Deal value also rose across most sectors but deal count lagged almost across the board.

    Public-to-private transactions continued to dominate the top-end of the market and represented roughly half the total deal value growth as GPs and their sovereign wealth and corporate investing partners took advantage of an improved financing environment for M&A in the US, and the opportunity to revamp companies out of the public eye.

    Exits revival eases liquidity logjam but larger cash flow challenge persists

    Last year’s sharp jump in exit value provided welcome relief for the PE industry from its stubborn liquidity challenge to sell enough companies to meet LPs’ demands for returns of liquidity to investors.

    A global M&A boom spurred by improving economic conditions, shifting business requirements, and AI helped to drive the rebound in exits. But Bain also notes that just seven mega-exits each valued at more than $10 billion added $155 billion, or 22%, to the $717 billion global value of 2025’s exits, while the total number of exits fell slightly to 1,570 – a 2% drop year-on-year that left exit count broadly in line with the level just before the Covid-19 pandemic.

    While exit activity was less pronounced across the broader market, exit value below the $10 billion threshold still grew by 34% as opportunistic buyers combed buyout portfolios for solutions to companies’ strategic imperatives. Sponsor-to-strategic exits, with sales to corporate buyers, regained importance. Exit value through this channel rose 66% year-on-year and even more strongly in North America (by 73%) and Europe (by 82%) – led by deals such as ECP’s $29.4 billion sales of Calpine, a US electricity generator, to rival energy group Constellation.

    The sponsor-to-sponsor channel was less robust, growing 21% globally, boosted by the Aligned Data Centers deal, without which the value of North American sponsor-to-sponsor exits would have dropped 19%. There was offsetting strong growth in Europe, where sales to sponsors rose 56% year-on-year.

    Initial public offerings globally increased 36% last year, from a very low base, and IPOs continued to provide only a minor exit route for PE, with GPs deterred from taking the option by complexity and the potential for macro turbulence to impact public markets. However, the reopened IPO window for exits raises the prospect of increased activity in the channel in 2026, Bain suggests.

    Amid industry-wide concern over liquidity, secondaries and continuation vehicles continued to expand as exit channels last year. For secondary deals, the transaction volume of GP- and LP-led vehicles rose 41% year-on-year.  GP-led continuation vehicles (CVs), allowing a fund to return capital to LPs while retaining control of the asset, grew even faster, by 62% year-on-year, marking 37% annual growth since 2022.

    Although CVs still accounted for less than 10% of total PE exit value, GPs’ interest in these is growing: a quarter of respondents to a recent StepStone/Bain survey said they had initiated or completed a CV in the past two years, and around 40% said they planned to explore a CV transaction in the next 12 to 24 months. More than half of respondents said generating liquidity was a primary reason for launching a CV.

    Overall, PE’s net cash flow moved modestly above the breakeven line last year, Bain finds. But with the key metric of distributions to LPs as a percentage of NAV still essentially flat at 14% for 2025 – a level not seen since 2008-09 during the global financial crisis – the report warns that PE’s liquidity challenge continues to dog the industry.

    Fund-raising falls for a fourth consecutive year as competition for capital further intensifies

    The continuing four-year-long drought in distributions to investors makes it unsurprising that PE funds continued to see fund-raising lag in 2025, Bain concludes.

    Private capital broadly raised $1.3 trillion last year, roughly even with 2024 totals, and thanks largely to strong growth in infrastructure funds. But fund-raising for buyout, the industry’s largest category, dropped 16% to $395 billion. Meanwhile, the total number of funds closed fell 18% for the industry as a whole and by 23% for buyout – marking a fourth straight year of decline, with almost every fund category affected.

    While Bain finds that a majority of LPs still expect to maintain or increase allocations to PE in coming years, it notes that investors are also increasingly constrained in making new commitments without cash flowing back to them from aging fund vintages. This is further reinforcing trends for LPs to gravitate to the largest, established GPs with consistent performance, and to become more demanding, with investors increasingly looking for top-quartile returns, alongside consistent, top-quartile cash distributions.

    In turn, Bain concludes that these trends are adding to the imperative facing GPs to define and articulate a differentiated and repeatable strategy as well as to transform how this is communicated with professionalized investor relations.

    Yet despite this intensified competitive pressure on funds, the report also concludes that PE’s value proposition remains appealing to investors. Top-quartile buyout funds continue to outperform public market averages significantly over all time horizons, Bain notes. A key appeal of PE for investors remains broader diversification across sectors and company sizes at a time when US equity markets have become extraordinarily concentrated, it adds.

    Media contacts
    To arrange an interview or for any questions, please contact:
    Dan Pinkney (Boston) — Email: [email protected]
    Gary Duncan (London) — Email: [email protected]
    Ann Lee (Singapore) — Email: [email protected]

    About Bain & Company

    Bain & Company is a global consultancy that helps the world’s most ambitious change makers define the future.

    Across 65 cities in 40 countries, we work alongside our clients as one team with a shared ambition to achieve extraordinary results, outperform the competition, and redefine industries. We complement our tailored, integrated expertise with a vibrant ecosystem of digital innovators to deliver better, faster, and more enduring outcomes. Our 10-year commitment to invest more than $1 billion in pro bono services brings our talent, expertise, and insight to organizations tackling today’s urgent challenges in education, racial equity, social justice, economic development, and the environment. We earned a platinum rating from EcoVadis, the leading platform for environmental, social, and ethical performance ratings for global supply chains, putting us in the top 1% of all companies. Since our founding in 1973, we have measured our success by the success of our clients, and we proudly maintain the highest level of client advocacy in the industry.

    SOURCE Bain & Company

    Continue Reading

  • IDFC First Bank slips 15% on suspected $65 mln fraud – Reuters

    1. IDFC First Bank slips 15% on suspected $65 mln fraud  Reuters
    2. IDFC First Bank probes suspected $65mn fraud in accounts of government entities  Business Recorder
    3. Letter To The Editor  Kashmir Reader
    4. Haryana mandates exclusive banking with public sector banks, drops IDFC First and AU Small Finance  The Economic Times
    5. IDFCFIRSTB.NS Stock Today: Rs 590cr Chandigarh Fraud in Focus – February 23  Meyka

    Continue Reading

  • Published at Solar Energy – Design of a SiC-Si moving packed-bed particle-to-sCO2 heat exchanger for high temperature concentrating solar power applications

    Published at Solar Energy – Design of a SiC-Si moving packed-bed particle-to-sCO2 heat exchanger for high temperature concentrating solar power applications

    Abstract:
    Particle-based concentrating solar power systems integrated with sCO2 power cycles offer high thermal efficiencies but require durable heat exchangers to transfer heat from high-temperature particles to the sCO2 working fluid. This study presents the design and optimization of a silicon carbide-silicon moving packed-bed heat exchanger for fabrication via binder jetting additive manufacturing. The heat exchanger was designed to withstand a 20 MPa sCO2 pressure and operate at particle inlet temperatures up to 750 °C. The final design features 152 sCO2 channels distributed across 19 plates, with elliptical corners and a minimum wall thickness of 3 mm. Flow restrictors at the sCO2 channel inlets significantly improved flow uniformity, reducing thermal stresses and achieving a structural reliability of 99 % under representative operating conditions. The heat exchanger delivers a thermal duty of 9 kW and a volumetric power density of approximately 1 MW/m3 in the channel region. Sensitivity studies confirmed the heat exchanger’s robustness under varying operating conditions, demonstrating its viability as a high-performance alternative to metallic heat exchangers for particle-based high-temperature concentrating solar power applications.

    Bipul Barua, Christopher P Bowen, Wenhua Yu, Wenchao Du, David M France, Kevin Albrecht, Mark C. Messner, Dileep Singh, Design of a SiC-Si moving packed-bed particle-to-sCO2 heat exchanger for high temperature concentrating solar power applications, Solar Energy, Volume 303, 2026, 114114, ISSN 0038-092X, https://doi.org/10.1016/j.solener.2025.114114

    Continue Reading

  • Exclusive | The Fundraising Tactic AI Startups Are Using to Juice Valuations – The Wall Street Journal

    1. Exclusive | The Fundraising Tactic AI Startups Are Using to Juice Valuations  The Wall Street Journal
    2. Here are the 17 US-based AI companies that have raised $100M or more in 2026  TechCrunch
    3. The Weekly Notable Startup Funding Report: 2/16/26  AlleyWatch
    4. AI Startups Funding 2026: 17 US Companies Secure Staggering $100M+ Rounds in Just Two Months  CryptoRank

    Continue Reading

  • 2026 Australia: Midyear Legal Market Update — Shifting growth and strategy

    2026 Australia: Midyear Legal Market Update — Shifting growth and strategy

    Australian law firms remain on solid ground at midyear, but a closer look reveals diverging strategies and early signs of structural change in the market

    Key findings:

        • The market remains strong, but growth is difficult — Australian law firms are still posting solid demand and rate growth in the first half of FY 2026, yet the pace is becoming more challenging to sustain.

        • Australia is no longer a single legal market, but three distinct ones — The report identifies three clearly differentiated law firm segments: Large firms leading demand growth through aggressive investment; Big 8 firms emphasizing pricing power and cost discipline; and Midsize firms pursuing steadier, more moderate growth.

        • Early signals suggest GenAI is reshaping productivity and leverage — Changes in hours worked across seniority levels point to possible early impacts of GenAI; and while overall productivity is stable, non‑equity partners and associates are logging fewer hours, while senior associates and equity partners are working more.


    The Australian legal market enters the back half of FY 2026 with strong topline numbers, but beneath the surface, the market is working harder to maintain its momentum. Firms are navigating slower rate growth, shifting demand patterns, and the early tremors of what may prove to be a generative AI-driven transformation.

    Solid footing, harder-won gains

    Australian law firms built an impressive track record over the post-pandemic era, and the first half of FY 2026 shows that run may not be over yet — although its character is changing. Demand growth of 4.8% year-to-date sits a full percentage point above the average quarterly pace since FY 2022, according to the Thomson Reuters Institute’s just-released 2026 Australia: Midyear Legal Market Update report. Worked rates, meanwhile, rose 4.7%, which is respectable, but a noticeable step down from the 5.4% average growth firms had enjoyed since FY 2022.

    At the practice level, the picture is broadly encouraging. Both transactional and counter-cyclical practice groups are accelerating, with workplace relations leading all practices at 9.9% year-to-date growth and corporate general close behind at 7.7%. However, a potential warning sign lies in the divergence among each macro-category’s flagship practice: insolvency & restructuring is surging at 7.9%, while mergers & acquisitions sits in contraction at -2.1%. If dealmaking remains subdued while restructuring activity accelerates, transactional practices could face meaningful headwinds in the quarters ahead.

    Three markets, not one

    Perhaps the most significant finding in this year’s report is what the market-wide averages have been concealing. Last year’s Australia State of the Legal Market report highlighted growing competition between the Big 8 and a broader group of Large law firms that were challenging the Big 8’s dominance. This year, a refined three-segment framework reveals that the former Large category was actually masking two very different stories, between Large firms and a newly identified set of Midsize firms.

    The newly delineated Large firms have emerged as the clear demand leaders, posting nearly 7% year-to-date growth — roughly double their peers — fueled by aggressive investment and expansion. The Big 8, by contrast, are leaning into pricing power and cost discipline, growing demand at a more measured 2.7%. And the Midsize cohort, at 2.4% demand growth, is charting a balanced, moderate course.

    The profitability divergence is even more striking. Since FY 2022, the firms now classified as Large have grown profits per lawyer by 27.4%, while Midsize firms managed just 3.1% — much closer to the Big 8’s 7.1% than to their former stablemates. What previously appeared to be a broad-based challenge to the elite was, in reality, concentrated among a smaller group of high performers that were pulling the average upward.

    Early signals of AI-driven change

    The report also surfaces a potentially significant development in law firm productivity. While overall hours worked per month ticked up slightly for the average qualified fee earner, the gains are unevenly distributed. Non-equity partners recorded their third consecutive productivity decline, and junior and mid-level associates are also slightly down. Yet senior associates and equity partners are logging more hours, keeping overall numbers stable. One possible explanation is GenAI — if firms are deploying these tools most heavily on research, drafting, and document review tasks that traditionally filled junior and mid-level associate hours, this is precisely the pattern we would expect to see. While it’s too early to draw solid conclusions, the distribution of hours may represent an early sign of how AI is beginning to reshape the traditional leverage model.

    There is also a note of caution from firms’ clients. Thomson Reuters Market Insights data shows Australian general counsel growing more conservative in their spending outlook, with net spend anticipation for overall legal work dropping to 0 points. That means just as many GCs see their legal spend increasing as those that anticipating it decreasing.

    Interestingly, international legal spend tells a different story — Australia-based GCs are increasingly looking outward, with the Asia-Pacific and Latin American regions emerging as areas of particular activity, while Europe has cooled. For Australian firms with cross-border ambitions, the short-term opportunity may lie to the global east and south rather than west.

    Looking into the second half of the year

    As the Australian legal market moves into the second half of FY 2026, the story is no longer one of uniform prosperity but rather, one of strategic differentiation. Demand remains healthy, profitability is solid, and expense discipline is improving; however, growth is no longer evenly distributed. The law firms that thrive in the quarters ahead will be those that understand which game they’re playing. In an increasingly segmented market, adaptability — not scale alone — will define success.


    You can download a full copy of the Thomson Reuters Institute’s “2026 Australia: Midyear Legal Market Update” report by filling out the form below:

    Continue Reading

  • CStone Announces MHRA Approval in UK for Sugemalimab in Stage III NSCLC

    • Following approval by the European Commission (EC), sugemalimab has received a new indication approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for stage III non-small cell lung cancer (NSCLC). This marks the second indication approved for the product in the UK.
    • This approval is based on the GEMSTONE-301 study, a multicenter, randomized, double-blind Phase III trial. Results demonstrated that sugemalimab provided statistically significant improvement in progression-free survival (PFS) and a clinically meaningful prolongation of overall survival (OS) in patients with stage III NSCLC.
    • To date, CStone has established four commercialization partnerships for sugemalimab across Europe, the Middle East and Africa, and Latin America, extending its reach to more than 60 countries and regions. The global commercial rollout is now actively underway.

    SUZHOU, China, Feb. 22, 2026 /PRNewswire/ — CStone Pharmaceuticals (“CStone,” HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, autoimmune/inflammation, and other key disease areas, today announced that the UK MHRA has granted a new indication for sugemalimab as a monotherapy for adult patients with unresectable stage III NSCLC with PD-L1 expression on ≥1% of tumour cells and no sensitising EGFR mutations, or ALK, ROS1 genomic aberrations and whose disease has not progressed following platinum-based chemoradiotherapy (CRT).

    Dr. Jason Yang, CEO, President of R&D, and Executive Director at CStone, stated, “Since its initial EU approval in July 2024, sugemalimab has become one of only two PD-(L)1 antibodies approved for stage III NSCLC in Europe, providing a comprehensive treatment option spanning both locally advanced, unresectable stage III and metastatic stage IV NSCLC. Its commercial footprint has now expanded to over 60 countries and regions globally, with market access applications approved or under regulatory review in more than ten countries. Furthermore, sugemalimab has been included in multiple national reimbursement systems—an affirmation of its recognized clinical value and pharmacoeconomic benefit.”

    Dr. Qingmei Shi, Chief Medical Officer of CStone, added, “The MHRA’s approval of sugemalimab for Stage III NSCLC represents another significant endorsement from a major international regulatory agency and will further unlock its global commercial potential. We are proud of CStone’s clinical development and regulatory affairs teams for their’ effective execution, invaluable experience in global registration, and ability to navigate mature regulatory frameworks in Europe and the UK. Sugemalimab in combination with chemotherapy treating stage IV NSCLC has received the highest-level recommendation [I, A] in the first-line setting for both squamous and non-squamous NSCLC in the European Society for Medical Oncology (ESMO) Non-Oncogene-Addicted Metastatic NSCLC Living Guideline. We look forward to the potential inclusion of this newly approved stage III NSCLC indication in this authoritative guideline in the near future. CStone will continue to advance regulatory filings for sugemalimab in additional indications, including gastric cancer (GC) and esophageal squamous cell carcinoma (ESCC).”

    About Sugemalimab

    The anti-PD-L1 monoclonal antibody sugemalimab was developed by CStone using OmniRat® transgenic animal platform, which allows creation of fully human antibodies in one step. Sugemalimab is a fully human, full-length anti-PD-L1 immunoglobulin G4 (IgG4) monoclonal antibody, which may reduce the risk of immunogenicity and toxicity for patients, a unique advantage over similar drugs.

    The EC and MHRA have approved sugemalimab for two indications:

    • In combination with platinum-based chemotherapy for the first-line treatment of patients with metastatic NSCLC with no sensitizing EGFR mutations, or ALK, ROS1 or RET genomic tumor aberrations; and
    • Monotherapy for adult patients with unresectable stage III NSCLC with PD-L1 expression on ≥1% of tumour cells and no sensitising EGFR mutations, or ALK, ROS1 genomic aberrations and whose disease has not progressed following platinum-based CRT. 

    The National Medical Products Administration (NMPA) of China has approved sugemalimab for five indications:

    • In combination with chemotherapy as first-line treatment of patients with metastatic squamous and non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations and metastatic squamous NSCLC;
    • For the treatment of patients with unresectable Stage III NSCLC whose disease has not progressed following concurrent or sequential platinum-based CRT;
    • For the treatment of patients with relapsed or refractory extranodal NK/T-cell lymphoma;
    • In combination with fluorouracil and platinum-based chemotherapy as first-line treatment of patients with unresectable locally advanced, recurrent or metastatic ESCC; and
    • In combination with fluoropyrimidine- and platinum-containing chemotherapy as first-line treatment for unresectable locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma with a PD-L1 expression CPS ≥5.

    About CStone

    CStone (HKEX: 2616), established in late 2015, is an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, autoimmune/inflammation, and other key disease areas. Dedicated to addressing patients’ unmet medical needs in China and globally, the Company has made significant strides since its inception. To date, the Company has successfully launched 4 innovative drugs and secured approvals for 20 new drug applications covering 9 indications. The company’s pipeline is balanced by 16 promising candidates, featuring potentially first-in-class or best-in-class antibody-drug conjugates (ADCs), multispecific antibodies, immunotherapies and precision medicines. CStone also prides itself on a management team with comprehensive experiences and capabilities that span the entire drug development spectrum, from preclinical and translational research to clinical development, drug manufacturing, business development, and commercialization.

    For more information about CStone, please visit: www.cstonepharma.com.

    Forward-looking statements

    The forward-looking statements made in this article only relate to events or information as of the date when the statements are made in this article. Except as required by law, we undertake no obligation to update or publicly revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. All statements in this article are made on the date of publication of this article and may change due to future developments.

    Disclaimer: only for communication and scientific use by medical and health professionals, it is not intended for promotional purposes.

    SOURCE CStone Pharmaceuticals

    Continue Reading

  • Stock market today: Live updates

    Stock market today: Live updates

    Traders work on the floor of the New York Stock Exchange (NYSE) on February 13, 2026 in New York City.

    Spencer Platt | Getty Images

    U.S. stock futures were little changed Sunday night after President Donald Trump said he’s raising his global tariffs to 15% from 10% after the Supreme Court struck down the president’s “reciprocal” tariffs.

    Dow Jones Industrial Average futures fell by 19 points, or 0.04%. S&P 500 futures and Nasdaq 100 futures dipped 0.07% and 0.14%, respectively.

    Trump on Saturday said he would increase global tariffs to 15%, up from the 10% he announced on Friday. Trump said the duties would go into effect immediately, though it was unclear whether any official documents had been signed regarding the timing.

    “I, as President of the United States of America, will be, effective immediately, raising the 10% Worldwide Tariff on Countries, many of which have been ‘ripping’ the U.S. off for decades, without retribution (until I came along!), to the fully allowed, and legally tested, 15% level,” Trump wrote.

    Trump also warned that additional levies would be coming over the next few months.

    Wall Street is coming off a choppy trading session. On Friday, stocks initially rallied after the Supreme Court struck down a broad swath of Trump’s trade agenda, before pulling back and then ultimately recovering again.

    The Dow Jones Industrial Average ended the session higher by more than 230 points, 0.5%, recovering from a 200-point loss earlier in the session. The S&P 500 gained 0.7%, while the Nasdaq Composite rose 0.9%.

    Investors hoped the Supreme Court ruling would soothe tensions between the U.S. and its trading partners and lead to possible refunds to companies affected by the tariffs, but are awaiting more clarity from the White House.

    “It would seem that Wall Street — and Main Street — are going to be dealing with the issue of trade and tariffs for some time to come,” Tim Holland, chief investment officer of Orion Wealth Management, wrote on Friday.

    Meanwhile, Iran remains a focal point for investors. This past week, Trump encouraged Iran to reach a deal over its nuclear program, warning that otherwise “bad things” might happen.

    Trump is scheduled to deliver his State of the Union address to Congress on Tuesday.

    Nvidia earnings will be a key focus this week. The chipmaking giant is set to release results on Wednesday. It’s one of only two Magnificent Seven stocks to have eked out a gain this year. The company will have to reassure investors that its artificial intelligence investment strategy remains intact.

    On the economic front, durable orders and factory orders data are set to be released on Monday morning.

    Continue Reading

  • Dollar Trades Within Range Amid Tariff Uncertainty: Markets Wrap

    Dollar Trades Within Range Amid Tariff Uncertainty: Markets Wrap

    (Bloomberg) — The US dollar traded in a tight range early Monday as uncertainty lingered after President Donald Trump lashed out at the US Supreme Court for striking down his use of emergency powers to impose so-called reciprocal tariffs.

    Risk currencies such as the Mexican peso edged lower while the euro and Japanese yen inched higher. The Thai baht, which is influenced by movements in gold, fluctuated. Bitcoin fell 1.4%.

    Trump said Saturday he would raise a 10% global tariff to 15% to preserve protective trade measures, stoking fresh economic turbulence after the Supreme Court ruling. The friction spilled out Sunday as Europe’s trade chief said he’ll propose halting ratification of a deal struck with the US, while India postponed talks to finalize an interim trade deal.

    “We’ve got so much experience of Trump now that we don’t think he’ll take this lying down,” said Nick Twidale, chief market analyst at AT Global Markets. “The increased uncertainty and question marks around what Trump will do next outweigh any potential positives from lower tariffs and potential paybacks.”

    Senior US officials said Trump’s tariff defeat at the Supreme Court won’t unravel deals negotiated with US partners.

    Those deals — which the administration made with partners including China, the European Union, Japan and South Korea — remain in place, US Trade Representative Jamieson Greer said Sunday on CBS’s Face the Nation.

    The S&P 500 added 0.7% Friday, notching its best week since Jan. 9, with optimism over the Supreme Court’s tariff ruling offsetting worries over heightened tensions between the US and Iran. An ETF tracking emerging markets hit all-time highs. The dollar slipped 0.2%, trimming its weekly advance to 0.6%.

    The yield on 10-year Treasuries rose two basis points to 4.08% in a volatile session Friday following mixed growth and inflation data before the tariff ruling added uncertainties over any potential budget shortfall. Treasuries are closed in Asian trading on Monday due to a holiday in Japan.

    Asian equity futures signaled a muted open in Australia, while Hong Kong shares looked set to rise, though the moves came before Trump announced the higher tariff rate. Equity markets in China remained closed for a holiday.

    In commodities, traders will be focusing on the oil market as the US and Iran are set to resume talks in Geneva in search of a diplomatic solution to the latest standoff over Tehran’s nuclear program.

    Some of the main moves in markets:

    Currencies

    The euro rose 0.1% to $1.1798 as of 6:01 a.m. Tokyo time The Japanese yen was little changed at 154.93 per dollar The offshore yuan was little changed at 6.8996 per dollar The Australian dollar was little changed at $0.7083 Cryptocurrencies

    Bitcoin fell 1.4% to $67,379.68 Ether fell 2.1% to $1,941 Stocks

    Hang Seng futures rose 1.7% on Friday Commodities

    West Texas Intermediate crude rose 0.1% to $66.48 a barrel Spot gold rose 2.2% to $5,107.45 an ounce This story was produced with the assistance of Bloomberg Automation.

    –With assistance from Michael G. Wilson.

    ©2026 Bloomberg L.P.

    Continue Reading